HFBD: a biomarker knowledge database for heart failure heterogeneity and personalized applications

MOTIVATION Heart failure (HF) is a cardiovascular disease with a high incidence around the world. Accumulating studies have focused on the identification of biomarkers for HF precision medicine. To understand the HF heterogeneity and provide biomarker information for the personalized diagnosis and treatment of HF, a knowledge database collecting the distributed and multiple-level biomarker information is necessary. RESULTS In this study, the HF biomarker knowledge database (HFBD) was established by manually collecting the data and knowledge from literature in PubMed. HFBD contains 2618 records and 868 HF biomarkers (731 single and 137 combined) extracted from 1237 original articles. The biomarkers were classified into proteins, RNAs, DNAs, and the others at molecular, image, cellular and physiological levels. The biomarkers were annotated with biological, clinical and article information as well as the experimental methods used for the biomarker discovery. With its user-friendly interface, this knowledge database provides a unique resource for the systematic understanding of HF heterogeneity and personalized diagnosis and treatment of HF in the era of precision medicine. AVAILABILITY The platform is openly available at http://sysbio.org.cn/HFBD/.

[1]  Bairong Shen,et al.  Physiological Informatics: Collection and Analyses of Data from Wearable Sensors and Smartphone for Healthcare. , 2017, Advances in experimental medicine and biology.

[2]  Marc A Pfeffer,et al.  Heart failure , 2005, The Lancet.

[3]  Bairong Shen,et al.  Computer-aided biomarker discovery for precision medicine: data resources, models and applications , 2019, Briefings Bioinform..

[4]  Nick Freemantle,et al.  Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. , 2007, European heart journal.

[5]  P. Zuchinali,et al.  Causes and Predictors of In-Hospital Mortality in Patients Admitted with or for Heart Failure at a Tertiary Hospital in Brazil , 2017, Arquivos brasileiros de cardiologia.

[6]  G R Sutherland,et al.  Assessing diagnosis in heart failure: which features are any use? , 1997, QJM : monthly journal of the Association of Physicians.

[7]  A. Mebazaa,et al.  Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure , 2014, Circulation.

[8]  Xin Qi,et al.  Decoding competing endogenous RNA networks for cancer biomarker discovery , 2020, Briefings Bioinform..

[9]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[10]  Bairong Shen,et al.  Renyi Distribution Entropy Analysis of Short-Term Heart Rate Variability Signals and Its Application in Coronary Artery Disease Detection , 2019, Front. Physiol..

[11]  A. Hoes,et al.  Clinical epidemiology of heart failure , 2007, Heart.

[12]  Bairong Shen,et al.  CHDGKB: a knowledgebase for systematic understanding of genetic variations associated with non-syndromic congenital heart disease , 2020, Database J. Biol. Databases Curation.

[13]  Jiajia Chen,et al.  Deciphering oncogenic drivers: from single genes to integrated pathways , 2015, Briefings Bioinform..

[14]  Hossam A. Hodeib,et al.  Diagnostic and Prognostic Value of Plasma Levels of Cardiac Myosin Binding Protein-C as a Novel Biomarker in Heart Failure , 2017, Pediatric Cardiology.

[15]  Hongxing He,et al.  Early Detection of Sudden Cardiac Death by Using Ensemble Empirical Mode Decomposition-Based Entropy and Classical Linear Features From Heart Rate Variability Signals , 2020, Frontiers in Physiology.

[16]  Volkmar Falk,et al.  2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.

[17]  R. F. Kelly,et al.  Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. , 2002, The American journal of medicine.

[18]  L. Lund.  Heart Failure with Mid-range Ejection Fraction: Lessons from CHARM. , 2018, Cardiac failure review.

[19]  Perry M. Elliott,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[20]  C. Fonseca,et al.  Prevalence of chronic heart failure in Southwestern Europe: the EPICA study , 2002, European journal of heart failure.

[21]  T. Thenappan,et al.  The heterogeneity of heart failure: will enhanced phenotyping be necessary for future clinical trial success? , 2014, Journal of the American College of Cardiology.

[22]  Bairong Shen,et al.  Translational Informatics for Parkinson’s Disease: from Big Biomedical Data to Small Actionable Alterations , 2019, Genom. Proteom. Bioinform..

[23]  Bairong Shen,et al.  Systems Health: A Transition from Disease Management Toward Health Promotion. , 2017, Advances in experimental medicine and biology.

[24]  Bairong Shen,et al.  CRC-EBD: Epigenetic Biomarker Database for Colorectal Cancer , 2020, Frontiers in Genetics.

[25]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[26]  Chen Shao,et al.  A Tool for Biomarker Discovery in the Urinary Proteome: A Manually Curated Human and Animal Urine Protein Biomarker Database* , 2011, Molecular & Cellular Proteomics.

[27]  Danny Chuon,et al.  Gastric Cancer (Biomarkers) Knowledgebase (GCBKB): A Curated and Fully Integrated Knowledgebase of Putative Biomarkers Related to Gastric Cancer , 2006, Biomarker insights.

[28]  Bairong Shen,et al.  Data-driven translational prostate cancer research: from biomarker discovery to clinical decision , 2020, Journal of Translational Medicine.

[29]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[30]  G. Novo,et al.  Biomarkers in heart failure. , 2009, Frontiers in bioscience.

[31]  J. McMurray,et al.  Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology , 2009, European journal of heart failure.

[32]  Bairong Shen,et al.  Phenotype–genotype network construction and characterization: a case study of cardiovascular diseases and associated non-coding RNAs , 2020, Database J. Biol. Databases Curation.

[33]  C. Lam,et al.  The middle child in heart failure: heart failure with mid‐range ejection fraction (40–50%) , 2014, European journal of heart failure.

[34]  C. Fonseca.  Diagnosis of heart failure in primary care , 2006, Heart Failure Reviews.

[35]  L. Lund.  The Inescapable Heterogeneity of Heart Failure. , 2017, Journal of cardiac failure.

[36]  D. Aarsland,et al.  Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials , 2018, Movement disorders : official journal of the Movement Disorder Society.

[37]  M. Woodward,et al.  Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial , 2017, Diabetes Care.

[38]  Ying Wang,et al.  Identifying novel prostate cancer associated pathways based on integrative microarray data analysis , 2011, Comput. Biol. Chem..